Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 23Breast Neoplasms 12Prostatic Neoplasms 11Triple Negative Breast Neoplasms 7Fallopian Tube Neoplasms 7Stomach Neoplasms 5Neoplasm Metastasis 5Sarcoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Metastatic Castration-resistant Prostate Cancer 4Fanconi Anemia, Complementation Group D1 4Small Cell Lung Carcinoma 3Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Endometrial Neoplasms 2

Interventions

olaparib 1cediranib 1bomedemstat 1atezolizumab 1Platinum 1Immunoglobulin G 1Etoposide 1Disulfides 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Extensive Stage Lung Small Cell Carcinoma × olaparib × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡